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Combined antiretroviral therapies have revolutionized
the prognosis of HIV disease transforming an almost uni-
formly lethal disease into a chronic one with an estimated
survival of several decades on effective antiretroviral ther-
apy. However, several issues had tempered this 'idyllic' sit-
uation: cART cannot be stopped without damages such as
increases in number of deaths and co-morbidities even at
relatively high ratio of CD4 demonstrating that HIV is not
only deleterious by its consequences on immune deficit
but also in the fact that it promotes high immune activa-
tion that follows the rebound in HIV replication – cART at
least NRTIs and PIs, is associated with toxicities and co-
morbidities. This leads us to investigate different drug-
class sparing maintenance strategies opening a new field
of research. PI monotherapy is currently investigated
mainly with lopinavir or darunavir under investigation in
two randomized studies – MONET in Europe and
MONOI in France through the ANRS network with results
available in 2009. The development of new classes of
drugs had already brought significant improvement in
HIV disease management. Integrase inhibitors mainly the
recently licensed raltegravir had led to increase in the rate
of full viral suppression in salvage patients in combina-
tion with new drugs from old classes such as darunavir or
etravirine and allowed up to over 80% of plasma HIV-
RNA <50 copies/ml. Inhibitors of coreceptors CCR5,
mainly maraviroc are not only antiretroviral agents but
also an immune modulatory agent with specific action on
CD4 lymphocytes, immune activation or potentially on
apoptosis. Because these drugs act on different viral tar-
gets, because of their different resistance and toxicity pro-
file from NRTIs or PIs, clinical research has to explore
their potential role in the treatment gaps. Several impor-
tant questions throughout remain to be explored: – What
is the role of these new drugs in primary infection? – How
can both raltegravir with its very rapid decrease in viral
load and maraviroc with its action on CD4 decrease the
delay needed time to control the virus and the time to
restore CD4 above 200/mm3 in late HIV presenters? –
How can these drugs be used in maintenance therapy in
patients with undetectable viral load but a long history
with subsequent toxicities of PIs or NNRTIs? – Can we
limit the number and the burden of drugs used to control
viral replication? – Will these drugs in addition to classic
cART be capable to decrease viral reservoirs and why not
tends towards eradication?
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